Anebulo Pharmaceuticals Inc

NASDAQ:ANEB  
2.96
-0.43 (-12.66%)
Earnings Announcements

Anebulo Pharmaceuticals Reports Q3 Loss Per Share Of $0.08

Published: 05/11/2022 13:21 GMT
Anebulo Pharmaceuticals Inc (ANEB) - Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates.
Q3 Loss per Share $0.08.
Cash and Cash Equivalents Were $16.5 Million As of March 31, 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.